# Paper Search: PD-1

**Date:** 2026-02-27 19:11 UTC
**Papers found:** 1
**Search time:** 1.9s

---

## 1. PD-1 and its ligands in tolerance and immunity.

**Authors:** Keir Mary E, Butte Manish J, Freeman Gordon J, Sharpe Arlene H
**Year:** 2008
**Journal:** Annual review of immunology
**Source:** pubmed
**CEBM Evidence Level:** 5

[Link](https://pubmed.ncbi.nlm.nih.gov/18173375/) | [DOI](https://doi.org/10.1146/annurev.immunol.26.021607.090331) | [PubMed](https://pubmed.ncbi.nlm.nih.gov/18173375/)

### Summary (Japanese)

PD-1とそのリガンド（PD-L1/PD-L2）は抑制性シグナルを介して、T細胞の活性化・免疫寛容・免疫病理のバランスを調節する。T細胞寛容の誘導と維持にはPD-1が重要で、非造血系細胞上のPD-L1はエフェクターT細胞応答を制限して組織障害を抑える。さらに微生物や腫瘍はPD-1:PD-L1経路を利用して抗感染・抗腫瘍免疫を弱め、慢性感染や腫瘍生存を促進する。PD-L1の追加結合相手としてB7-1が同定され、PD-L1–B7-1間の双方向の抑制性相互作用が、B7:CD28ファミリーによる免疫調節の新たな理解を示す。本レビューはこれらの機能と治療応用可能性を概説する。

<details>
<summary>Abstract (English)</summary>

Programmed death 1 (PD-1) and its ligands, PD-L1 and PD-L2, deliver inhibitory signals that regulate the balance between T cell activation, tolerance, and immunopathology. Immune responses to foreign and self-antigens require specific and balanced responses to clear pathogens and tumors and yet maintain tolerance. Induction and maintenance of T cell tolerance requires PD-1, and its ligand PD-L1 on nonhematopoietic cells can limit effector T cell responses and protect tissues from immune-mediated tissue damage. The PD-1:PD-L pathway also has been usurped by microorganisms and tumors to attenuate antimicrobial or tumor immunity and facilitate chronic infection and tumor survival. The identification of B7-1 as an additional binding partner for PD-L1, together with the discovery of an inhibitory bidirectional interaction between PD-L1 and B7-1, reveals new ways the B7:CD28 family regulates T cell activation and tolerance. In this review, we discuss current understanding of the immunoregulatory functions of PD-1 and its ligands and their therapeutic potential.

</details>

---

## References

1. Keir Mary E, Butte Manish J, Freeman Gordon J et al. (2008). PD-1 and its ligands in tolerance and immunity.. Annual review of immunology. doi:10.1146/annurev.immunol.26.021607.090331

*Generated by JARVIS Research OS on 2026-02-27 19:11 UTC*